MKI67 and breast carcinoma: Several studies have shown that breast carcinomas can be stratified into subtypes with different prognoses and treatment responses, similarly to those defined by the genomic portraits, using a set of four[6-10] or six[11-15] immunohistochemical markers, including the assessment of a proliferation marker such as Ki-67 in both definitions.